Novartis Deal Accretive From Day One, Witty Says

Novartis Deal Accretive From Day One, Witty Says Play

April 22 (Bloomberg) -- Andrew Witty, chief executive officer of GlaxoSmithKline PLC, talks about Novartis AG's agreement buy Glaxo's cancer drugs for as much as $16 billion while selling most of the company’s vaccines division to Glaxo for $7.1 billion. Witty speaks with Tom Keene and Scarlet Fu on Bloomberg Television's "Surveillance." (Source: Bloomberg)

  • On Air Now

    Bloomberg West Watch Now

  • Next

    Bloomberg Bottom Line

blog comments powered by Disqus